Arcutis director Howard Welgus proposes $133K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. director Howard Welgus reported a proposed sale of 4,728 common shares, with an approximate sale date of November 16, 2026, and an aggregate market value of $133,140.48. The stated Rule 10b5-1 plan adoption or instruction date is March 13, 2026.
The shares listed for sale include 634 shares from restricted-stock vesting on June 4, 2026, and shares from stock-option exercises: 822 acquired November 20, 2019; 1,018 acquired May 31, 2023; and 2,254 acquired June 14, 2024. Welgus also reported sales of 4,730 shares on September 15, 2026, and 4,728 shares on October 15, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Vesting financial
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.